Interferón Omega
Interferon Omega
Recombinant Omega Interferon of Feline Origin, rFelFN-w
También conocido como: Virbagen Omega · interferon-w · IFN-w (feline recombinant) · rFelFN-w · rFeIFN-omega · Feline interferon omega
Revisado por el equipo veterinario de VetSheetActualizado 5 abr 2026Referencia veterinaria basada en la evidencia
Las dosis son una referencia clínica para profesionales veterinarios autorizados. Confirme siempre con el prospecto actual y cada paciente individual.
Dosis por especie
🌎 NA — North America🌍 EU — Europe
Perros
| Indicación | Dosis | Vía | Frecuencia | Duración | Región |
|---|---|---|---|---|---|
| Treatment of parvovirus (enteric form) | 2.5 million Units/kg IV once daily | IV | q24h | 3 days | 🌎 NA |
| Treatment of atopic dermatitis | Dogs 8-15 kg = 1 million Units; 15-29 kg = 2 million Units; 29-40 kg = 3 million Units; >40 kg = 4 million Units | SC | Specific days | Days 0, 3, 7, 14, 21, 35, 56, 90, 120, & 150 | 🌎 NA |
| Parvovirus | 2.5 million units/kg | IV | q24h | 3 days | 🌍 EU |
- Treatment of parvovirus (enteric form): The earlier the dog is treated, the more likely of success.
- Treatment of atopic dermatitis: Further larger-scale studies needed to confirm cost-effectiveness and safety for long-term treatment.
Gatos
| Indicación | Dosis | Vía | Frecuencia | Duración | Región |
|---|---|---|---|---|---|
| Treatment of FeLV and/or FIV (non-terminal clinical stages) | 1 million Units/kg SC once daily | SC | q24h | 5 days (Three separate 5-day treatments performed at day 0, day 14, and day 60) | 🌎 NA |
| FHV-1 facial dermatitis | Day 0: 1.5 million Units/kg (half peri-lesionally/intradermally, half SC). Day 2 and 9: 1.5 million Units/kg SC. Days 19, 21, and 23: 0.75 million Units/kg peri-lesionally/intradermally + 0.75 million Units/kg SC. | SC / Intradermal / Peri-lesional | Specific days | 23 days | 🌎 NA |
- FHV-1 facial dermatitis: Cat was sedated with propofol for peri-lesional and intradermal injections.
Las dosis son una referencia clínica para profesionales veterinarios autorizados. Confirme siempre con el prospecto actual y cada paciente individual.
Resumen
El interferón omega es un interferón de tipo I recombinante de origen felino. Actúa como un potente inmunomodulador y agente antiviral.
- Uso veterinario: Se utiliza principalmente en medicina veterinaria para el tratamiento de infecciones virales graves, notablemente parvovirus canino y retrovirus felinos (FeLV y FIV).
- Eficacia entre especies: Perla clínica: Aunque es una proteína de origen felino, es altamente eficaz en perros porque los interferones de tipo I comparten afinidad por los receptores entre especies. Sin embargo, el uso prolongado en perros puede conducir a la formación de anticuerpos neutralizantes.
- Usos emergentes: Ha mostrado beneficios potenciales en el tratamiento de la dermatitis atópica canina, la peritonitis infecciosa felina (PIF), el calicivirus felino (FCV) y la dermatitis o queratitis por herpesvirus felino (FHV-1).
- Disponibilidad: Está disponible comercialmente en la UE y otras regiones, pero no está disponible comercialmente en los EE. UU. (requiere importación legal para uso compasivo).
Mecanismo de acción
Interferon-omega does not act as a direct virucidal agent. Instead, it induces an antiviral state in host cells:
- Receptor Binding: Binds to specific type I interferon receptors on the surface of target cells.
- Signal Transduction: Activates the JAK-STAT signaling pathway.
- Gene Transcription: Induces the transcription of interferon-stimulated genes (ISGs).
- Antiviral Proteins: Leads to the production of key enzymes such as 2'-5' oligoadenylate synthetase (OAS) and protein kinase R (PKR).
- Viral Inhibition: These enzymes inhibit viral mRNA translation and degrade viral RNA → effectively halting viral replication.
Additionally, it nonspecifically enhances host immune defense mechanisms by stimulating natural killer (NK) cells and macrophages.
Seguridad y advertencias
Contraindicaciones
- Concurrent vaccination in dogs (wait until fully recovered)
- Vaccination in cats during and after treatment (due to the immunosuppressive nature of FeLV/FIV)
- Substitution with human interferons (alpha, beta, or gamma)
- No specific contraindications available in the monograph
Efectos adversos
- Hyperthermia (typically 3-6 hours post-dose)
- Vomiting
- Soft feces or mild diarrhea (cats)
- Transient fatigue or lethargy (cats)
- Slight decreases in RBCs, WBCs, and platelets (usually resolves within a week)
- Increased ALT (usually resolves within a week)
- Antibody formation in dogs (with prolonged or repeated treatment)
- Mild diarrhoea
- Decreased WBCs (leukopenia)
- Decreased platelets (thrombocytopenia)
- Decreased RBCs (anaemia)
- Increased liver enzyme activities
- Ocular irritation (with topical use in cats)
- Immune-mediated diseases (reported with long-term administration in humans)
Precauciones
Do not vaccinate dogs currently being treated until they have fully recovered. Cat vaccinations are contraindicated during and after treatment due to the underlying immunosuppressive retroviral infections. Intravenous administration in cats may cause an increased incidence and severity of adverse effects, though adverse effects in cats are generally uncommon. Dogs may develop neutralizing antibodies if treatment is prolonged beyond the labeled dosage period.
Interacciones farmacológicas
May increase the risk of liver toxicity; use with caution.
May increase the risk of bone marrow suppression; use with caution.
Should not be administered concurrently until the animal has clinically recovered.
Improves prognosis; no negative interactions observed.
Improves prognosis; no negative interactions observed.
Monitorización
- Clinical efficacy (resolution of viral infection signs)
- Complete Blood Count (CBC) to monitor for myelosuppression
- Hepatic function tests (ALT)
- Complete Blood Count (WBCs, RBCs, platelets)
- Liver enzyme activities
- Body temperature
- Clinical signs of gastrointestinal upset or fatigue
Farmacocinética
Vida media
Absorción
Rapidly bound to specific receptor sites on a variety of cells after intravenous injection.
Distribución
Highest tissue levels are found in the liver and kidneys. In dogs, volume of distribution (Vd) at steady state is about 0.1 L/kg.
Metabolismo
Catabolized in the kidneys.
Eliminación
Filtered in the renal glomeruli. Total body clearance in dogs is 6.9 mL/min/kg.
Sobredosis
In safety studies, 10X overdoses in dogs and cats caused mild lethargy/somnolence, slight hyperthermia, and slight increases in respiratory and heart rates. In all animals tested, clinical signs resolved within 7 days and no specific treatment was required.
Productos disponibles
Formulaciones
- Lyophilized powder for injection: 10 million Units/vial
- Lyophilized powder for injection: 5 million Units/vial
- 10 million units/vial powder with solvent for reconstitution
Veterinario
- Virbagen Omega 10 million Units/vial
- Virbagen Omega 5 million Units/vial
Estado regulador
Authorized for veterinary use in the EU.
POM-V classification.
Sin datos reguladores para: 🇺🇸 US · 🇭🇰 HK · 🇹🇼 TW · 🇯🇵 JP · 🇰🇷 KR · 🇦🇺 AU
Almacenamiento y estabilidad
Store in its original carton in the refrigerator (4°C ± 2°C) and protect from freezing. Shelf life is 2 years when properly stored. Once reconstituted with the supplied isotonic sodium chloride solution, it contains no preservatives and should ideally be used immediately; however, the reconstituted solution is reported to be stable for at least 3 weeks when refrigerated. Do not mix with any other vaccine or immunological product.
Información para el cliente
Nota importante: Este medicamento se administra habitualmente en un entorno hospitalario veterinario donde su mascota puede ser monitoreada y recibir soporte de cerca, especialmente dado que a menudo se utiliza para infecciones virales graves como el parvovirus.
- Qué esperar: Su mascota puede desarrollar una fiebre leve de 3 a 6 horas después de la inyección. Esta es una respuesta inmunitaria normal al medicamento. También pueden ocurrir vómitos leves, cansancio o heces blandas.
- Vacunaciones: No vacune a su mascota mientras esté recibiendo este tratamiento. Para gatos con FeLV o FIV, generalmente no se recomiendan las vacunas incluso después del tratamiento debido a su sistema inmunológico comprometido.
- Costo: El tratamiento con interferón omega implica tecnología recombinante avanzada y puede ser muy costoso. Discuta los costos esperados y el pronóstico con su veterinario.
La referencia de medicamentos de VetSheet está destinada a profesionales veterinarios autorizados como ayuda para la toma de decisiones clínicas, no como sustituto del criterio profesional ni del prospecto actual del fabricante.